Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide

Bone Marrow Transplantation volume 53, pages 169–174 (2018)Cite this article

Subjects

Abstract

Mixed chimerism (MC) occurs frequently after allogeneic hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) and may be associated with rejection. We report the outcome of MC in 132 TM patients conditioned with Busulphan/Cyclophosphamide, who had successful engraftment and had ⩾1 year follow-up. Chimerism was first assessed at day +28, then every 3–9 months or more frequently if there was MC. If rejection was suspected, immunosuppression was stopped and donor-lymphocyte infusion (DLI) was given if there was no response. Among 132 patients, aged 7 years (range: 2–24), 46/132 (34.8%) had MC in the first year, 32/46 (69.6%) at day +28 and another 14 (30%) between day +28 and 1 year post HSCT. MC was quantified at level 1 (residual host chimerism (RHC) <10%) in 20 (43.5%), level II (RHC 10–25%) in 14 (30.4%) and level III (RHC >25%) in 12 (26.1%). On tapering immunosuppression, 15 (32.6%) developed acute GvHD and 8 (17.4%) had chronic GvHD with reversal to complete chimerism (CC). DLI was administered to 5/46 (10.9%), 1 evolved to CC but 4 rejected the graft. At median follow-up of 60 months (range: 16–172), 20/46 (43.5%) had CC, 18/46 (39.1%) had persistent MC with hemoglobin of 11.5 g/dL (range: 8.4–13.6), whereas 8 (17.4%) rejected the graft. Close monitoring and early intervention is needed with increasing recipient chimerism. Novel strategies are required for preventing graft rejection.

This is a preview of subscription content, access via your institution

Access options

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Andreani M, Testi M, Gaziev J, Condello R, Bontadini A, Tazzari PL et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica 2011; 96: 128–133.

    Article  Google Scholar 

  2. Andreani M, Testi M, Lucarelli G . Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance: persistent mixed chimerism and immune tolerance. Tissue Antigens 2014; 83: 137–146.

    Article  CAS  Google Scholar 

  3. Angelucci E, Baronciani D . Allogeneic stem cell transplantation for thalassemia major. Haematologica 2008; 93: 1780–1784.

    Article  Google Scholar 

  4. Hsieh MM, Wu CJ, Tisdale JF . In mixed hematopoietic chimerism, the donor red cells win. Haematologica 2011; 96: 13–15.

    Article  Google Scholar 

  5. Hsieh MM, Wu CJ, Tisdale JF . In mixed hematopoietic chimerism, the donor red cells win. Haematologica 2011; 96: 13–15.

    Article  Google Scholar 

  6. Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494–3499.

    CAS  PubMed  Google Scholar 

  7. Andreani M, Testi M, Battarra M, Lucarelli G . Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism 2011; 2: 21–22.

    Article  Google Scholar 

  8. Andreani M, Testi M, Battarra M, Indigeno P, Guagnano A, Polchi P et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus 2008; 6: 143–149.

    PubMed  PubMed Central  Google Scholar 

  9. Amrolia PJ, Vulliamy T, Vassiliou G, Lawson S, Bryon J, Kaeda J et al. Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation. Br J Haematol 2001; 114: 219–225.

    Article  CAS  Google Scholar 

  10. Lucarelli G, Clift RA, Galimberti M, Polchi P, Angelucci E, Baronciani D et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87: 2082–2088.

    CAS  PubMed  Google Scholar 

  11. Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Dennison D et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia–the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005; 36: 839–845.

    Article  CAS  Google Scholar 

  12. Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A et alImproved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts.PLoS ONE 2013 8 e61637.

    Article  CAS  Google Scholar 

  13. Sellathamby S, Balasubramanian P, Sivalingam S, Shaji RV, Mathews V, George B et al. Developing an algorithm of informative markers for evaluation of chimerism after allogeneic bone marrow transplantation. Bone Marrow Transplant 2006; 37: 751–755.

    Article  CAS  Google Scholar 

  14. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618.

    Article  CAS  Google Scholar 

  15. Andreani M, Nesci S, Lucarelli G, Tonucci P, Rapa S, Angelucci E et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401–404.

    Article  CAS  Google Scholar 

  16. Balasubramanian P, Desire S, Sugumaran P, ML K, Abraham A, Viswabandya A et al. Trough level of first dose of busulfan (Cmin1) is a stronger predictor of graft rejection than steady state concentration (Css1) in patients with beta thalassemia major undergoing allogeneic hematopoietic stem cell transplantation. Blood 2015; 116: 518.

    Google Scholar 

  17. Balasubramanian P, Desire S, Panetta JC, Lakshmi KM, Mohanan E, Viswabandya A et al. Pharmacokinetics of cyclophosphamide metabolites influence outcome in patients with β-thalassemia major undergoing allogeneic HSCT. Blood 2015; 118: 1941.

    Google Scholar 

  18. Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A et al. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant 2016; 51: 813–818.

    Article  CAS  Google Scholar 

  19. Anurathapan U, Pakakasama S, Mekjaruskul P, Sirachainan N, Songdej D, Chuansumrit A et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transplant 2014; 20: 2066–2071.

    Article  Google Scholar 

  20. Andreani M, Gianolini ME, Testi M, Battarra M, Tiziana G, Morrone A et al. Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation. Chimerism 2014; 5: 75–79.

    Article  Google Scholar 

  21. Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U et al. Early recipient chimerism testing in the T-and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia 2012; 26: 509–519.

    Article  CAS  Google Scholar 

  22. Rajasekar R, Mathews V, Lakshmi KM, George B, Viswabandya A, Chandy M et al. cellular immune reconstitution and its impact on clinical outcome in children with β thalassemia major undergoing a matched related myeloablative allogeneic bone marrow transplant. Biol Blood Marrow Transplant 2009; 15: 597–609.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Christian Medical College, Vellore, India

    N A Fouzia, E S Edison, K M Lakshmi, A Korula, S R Velayudhan, P Balasubramanian, A Abraham, B George, V Mathews & A Srivastava

  2. Princess Margaret Hospital, Toronto, ON, Canada

    A Viswabandya

Authors
  1. N A Fouzia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E S Edison
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K M Lakshmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Korula
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S R Velayudhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Balasubramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Viswabandya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B George
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V Mathews
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Srivastava.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fouzia, N., Edison, E., Lakshmi, K. et al. Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide. Bone Marrow Transplant 53, 169–174 (2018). https://doi.org/10.1038/bmt.2017.231

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.231

This article is cited by

Search

Advanced search

Quick links